GenSci Partners with Leading AI Company Partex AI to Accelerate Drug Development and Global Commercialization

Recently, Changchun GeneScience Pharmaceutical Co., Ltd. ("GenSci") announced a strategic collaboration with Partex AI, a pioneering AI-driven biopharmaceutical company, to accelerate innovative drug development. By combining GenSci's decades of experience in developing innovative drugs for major diseases with Partex AI's advanced AI technologies, this collaboration aims to speed up the discovery, development and commercialization of innovative therapies.

Under the partnership, GenSci and Partex AI will leverage Partex AI's Foundation Model and AI-based drug discovery and development technology platform to screen and optimize new drug candidates and identify new therapeutic targets, which is expected to support the expansion of GenSci's core therapeutic areas and advance global commercialization.

Xian Xuan, PhD, Head of Artificial Intelligence Drug Institute at GenSci, commented, "We are pleased to collaborate with Partex AI and fully leverage its cutting-edge technologies to advance target discovery and enhance indications. This partnership will strengthen our capabilities in AI-enabled drug development and help bring innovative treatment options from China to patients worldwide."

Zhao Lisha, Head of Partex AI Asia, added, "This strategic cooperation leverages the complementary strengths of GenSci and Partex AI. We aim to advance promising programs more effectively and support decision-making across the full drug development process to address unmet clinical needs."

AI has become a critical enabler of GenSci's innovation strategy, empowering multiple areas such as drug discovery, development, patient services, and commercialization. GenSci's in-house AI platforms, including GenMOL and GenROS, have significantly improved R&D efficiency. This partnership will further advance GenSci's AI-driven strategy, reinforcing its commitment to innovation.

About Partex AI

Partex AI is a pioneering AI-driven biopharmaceutical company dedicated to revolutionizing drug discovery and development. By harnessing cutting-edge AI technologies, Partex aims to accelerate the identification, development, and commercialization of breakthrough therapies. The company's proprietary platform uses advanced techniques to identify new drug candidates, predict therapeutic applications, and accelerate the in-& out-licensing process, helping to bring novel therapies to market faster.

GenSci is a leading biopharmaceutical company in China, specialising in pediatric and women's health. Additionally, GenSci is active in four other therapeutic areas: Endocrinology, Metabolic, Immunology/Respiratory, and Oncology. The company has over 9,000 employees, and integrates research, development, production, and marketing of innovative therapies in its value chain. Established in 1997, the company is a subsidiary of Changchun High-Tech Industries (Group) and is headquartered in Changchun, China.